Key Points Interested in GSK PLC Sponsored ADR? Here are five stocks we like better. GSK is expanding oncology across lung, ...

The GSK-3 inhibitor market is gaining momentum, not due to older drugs like lithium, but rather to newer, more targeted programs currently in mid- and late-stage development. These could change how ...

GSK stock increased 0.4% following Berenberg's upgrade to buy with £22 target and announcement of $750M Chimagen deal for multiple myeloma therapy.

On Monday, GSK plc GSK stock is trading higher on highly positive clinical data from two separate lung cancer trials, ...

GSK shares climbed after the company reported encouraging clinical trial results for two lung cancer treatments, strengthening its oncology strategy despite mixed analyst views on the stock.

Phase I first-in-human trial of ABT-301, an oral pan-HDAC inhibitor, in patients with advanced solid tumors. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does ...